ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Astellas Pharma Inc (OP:ALPMY)

13.86 -0.05 (-0.36%)

Streaming Delayed Price Updated: 3:59 PM EST, Jan 30, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	94,738
Open	13.90
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	13.91
Today's Range	13.86 - 13.96
52wk Range	8.370 - 14.72
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power ↗

November 12, 2025

Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.

Via Benzinga

Performance

YTD	+4.1%	+4.1%
1 Month	+4.3%	+4.3%
3 Month	+32.8%	+32.8%
6 Month	+31.1%	+31.1%
1 Year	+40.1%	+40.1%

More News

Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients ↗

October 18, 2025

Via Investor's Business Daily

Why Is Taysha Gene Therapies Stock Falling Friday? ↗

October 17, 2025

Via Benzinga

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients ↗

August 12, 2025

Via Benzinga

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study ↗

July 10, 2025

Via Benzinga

JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗

March 18, 2025

Via Benzinga

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo ↗

February 11, 2025

Via Benzinga

Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise ↗

January 03, 2025

Via Benzinga

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact ↗

December 31, 2024

Via Benzinga

1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst ↗

October 29, 2024

Via The Motley Fool

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗

October 16, 2024

Via Benzinga

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Via Investor's Business Daily

Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data ↗

August 05, 2024

Via Benzinga

MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗

February 22, 2024

Via Talk Markets

Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal ↗

December 31, 2023

Via Talk Markets

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗

December 29, 2023

Via Benzinga

How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks ↗

October 22, 2023

Via Investor's Business Daily

Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study ↗

October 05, 2023

Via Benzinga

Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years ↗

September 24, 2023

Via The Motley Fool

Why Is Seagen Stock Trading Higher Today? ↗

September 22, 2023

Via Benzinga

Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer ↗

September 22, 2023

Via Investor's Business Daily

What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? ↗

September 20, 2023

Via Benzinga

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

September 01, 2023

Via MarketBeat

Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin ↗

August 07, 2023

Via Investor's Business Daily

Frequently Asked Questions

Is Astellas Pharma Inc publicly traded?

Yes, Astellas Pharma Inc is publicly traded.

What exchange does Astellas Pharma Inc trade on?

Astellas Pharma Inc trades on the OTC Traded

What is the ticker symbol for Astellas Pharma Inc?

The ticker symbol for Astellas Pharma Inc is ALPMY on the OTC Traded

What is the current price of Astellas Pharma Inc?

The current price of Astellas Pharma Inc is 13.86

When was Astellas Pharma Inc last traded?

The last trade of Astellas Pharma Inc was at 01/30/26 03:59 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.